कंपनी का अवलोकन
Entrada Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to transforming patient outcomes by developing a novel class of medicines that target intracellular sites previously deemed inaccessible. The company functions within the Healthcare sector and specifically within the Biotechnology industry, focusing on the creation of Endosomal Escape Vehicle therapeutic candidates. Its current scale is defined by a market capitalization of $548.23M, an annualized revenue of $25.42M, and an workforce of 152 employees. The market cap figure of $548.23M indicates a mid-cap valuation typical for early-stage biotech firms that are investing heavily in research and development rather than generating substantial profits, while the revenue of $25.42M reflects the current commercial scale of its pipeline, suggesting the company is still in the phase of establishing its market presence.
वित्तीय स्वास्थ्य
The company reported revenue of $25.42M over the trailing twelve months, yet it recorded a net income of $-143,750,000 and an EBITDA of $-151,902,000, highlighting a significant disparity where operating expenses vastly exceed top-line earnings. This substantial gap between revenue and net income reveals a cost structure heavily weighted towards research, development, and administrative costs that have not yet been offset by profitable operations. The free cash flow stands at $-76,957,752, indicating that the company is burning cash at a rapid pace, which limits its immediate financial flexibility and reliance on external capital sources. All three margin metrics reflect this financial reality: the gross margin is 0.0%, the operating margin is -3103.0%, and the profit margin is 0.0%, collectively signaling that the company is not yet profitable and faces immense pressure to reduce costs or increase sales volume. The balance sheet holds $295.70M in cash against $50.93M in debt, supported by a debt-to-equity ratio of 16.64, which suggests a capital structure dominated by equity financing rather than traditional leverage. Despite the high debt-to-equity figure, the current ratio of 12.53 indicates extremely strong short-term liquidity, providing ample buffer to cover immediate obligations. However, the return on equity is -39.1% and the return on assets is -21.6%, metrics that reveal management has yet to generate positive returns on the capital invested in the business.
मूल्यांकन आकलन
Valuation multiples for Entrada Therapeutics show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at -4.16, implying that the market currently prices the stock based on future earnings expectations that are not yet realized. The price-to-book ratio is 1.68, which indicates that the market values the company at a premium of 68% over its net asset value, reflecting confidence in the potential of its unproven therapeutic pipeline. Alternative valuation metrics include a price-to-sales ratio of 21.57 and an EV/EBITDA of -1.78, suggesting that investors are paying a high multiple relative to sales revenue given the lack of profitability. The stock has traded between a 52-week high of $14.36 and a 52-week low of $4.93, meaning the current trading price sits within a wide volatility range driven by biotech sector sentiment. The beta value is -0.15, a unique metric indicating that the stock's price volatility moves inversely to the broader market or with an extremely low correlation, presenting a distinct risk profile compared to standard equities.
Growth & Income
The revenue growth year-over-year is -96.5%, while earnings growth is N/A, indicating that the company is experiencing a contraction in top-line sales, likely as it transitions between product cycles or faces market challenges. The decline in revenue relative to earnings growth (which is not applicable) suggests that the company is struggling to maintain its sales base in the current market environment. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute profits to shareholders, which is consistent with its strategy of reinvesting all available resources into research and development. Consequently, the overall growth and income profile is characterized by a lack of current income generation and significant revenue contraction, relying entirely on future potential rather than existing cash flows or dividend distributions.